



Biotech Daily

Monday July 17, 2023

Daily news on ASX-listed biotechnology companies

- * **ASX FLAT, BIOTECH UP: CYCLOPHARM UP 5%; UNIVERSAL BIO DOWN 6%**
- * **CYCLOPHARM RECORD H1 UNAUDITED REVENUE UP 39% TO \$15m**
- * **CLEO DIAGNOSTICS \$12m IPO FOR OVARIAN CANCER BLOOD TESTS**
- * **QUEENSLAND UNI \$3m RADIO-METAL CANCER THERAPY FACILITY**
- * **BIOXYNE: AMAZON SELLS BREATHE DR WATSON MUSHROOMS**
- * **PLATINUM TAKES 19.9% OF ADALTA**
- * **GEOFFREY POCOCK DILUTED BELOW 5% OF ARGENICA**
- * **DIRECTOR STEVEN FORMICA TAKES 5% ECHO IQ**
- * **PLANET INNOVATION DILUTED TO 16% IN LUMOS**
- * **DAVID SIESTMA INCREASES, DILUTED TO 8% IN PYC**
- * **ONCOSIL APPOINTS DR GABRIEL LIBERATORE DIRECTOR**
- * **IMAGION BOB PROULX NON-EXECUTIVE CHAIR**

MARKET REPORT

The Australian stock market slipped 0.06 percent on Monday July 17, 2023, with the ASX200 down 4.6 points to 7,298.5 points. Eighteen of the Biotech Daily Top 40 stocks were up, 14 fell, six traded unchanged and two were untraded.

Cyclopharm was the best, up 11 cents or 5.1 percent to \$2.28, with 17,449 shares traded, followed by Alcidion up 5.0 percent to 10.5 cents with 975,362 shares traded. Starpharma climbed 4.4 percent; Avita and Kazia were up three percent or more; Actinogen, Compumedics, Dimerix, Impedimed and Polynovo rose more than two percent; Nanosonics, Orthocell, Proteomics, Resmed and SDI were up more than one percent; with 4D Medical, Clinuvel, Cochlear, Medical Developments and Pro Medicus up by less than one percent.

Universal Biosensors led the falls, down 1.5 cents or six percent to 23.5 cents, with 25,000 shares traded. Atomo lost 5.6 percent; Micro-X fell 4.55 percent; Next Science, Nova Eye, Prescient and Volpara were down more than three percent; Imugene, Paradigm and Resonance all shed two percent; Neuren, Opthea, Pharmaxis and Telix were down one percent or more; with CSL down by 0.8 percent.

CYCLOPHARM

Cyclopharm says it expects “record” unaudited group sales revenue for the six months to June 30, 2023 up 39 percent to \$15.3 million, compared to the prior period.

Cyclopharm said that revenue from sales of its Technegas generators and Technegas consumable patient administration sets were steady at \$7.5 million, with third-party sales exceeding Technegas sales for the first time at \$7.7 million.

The company said it had cash reserves of about \$18.9 million at June 30, 2023 and was in a “strong” position to launch Technegas in the US.

Cyclopharm managing-director James McBrayer said the company’s performance for the first half of 2023 “reflects the underlying strength of our core business”.

“A standout performance in third-party sales also highlights the ability to leverage our global sales, service and regulatory infrastructure, to not only support our core Technegas technology across 64 countries, but to continue to expand our earnings base with the successful sale and service of third-party products in Cyclopharm’s 18 direct markets,” Mr McBrayer said.

The company said it expected US Food and Drug Administration approval by September 29, 2023, allowing it to sell Technegas in the US in the second half of 2023.

Cyclopharm was up 11 cents or 5.1 percent to \$2.28.

CLEO DIAGNOSTICS

Cleo Diagnostics says it hopes to raise \$12 million at 20 cents a share to list on the ASX under the code COV to commercialize its non-invasive blood tests for ovarian cancer.

Cleo said it would have an indicative market capitalization of about \$25.7 million following the initial public offer, and hoped to be quoted on the ASX on August 18, 2023.

The company said that its blood diagnostic aimed to detect early stages of ovarian cancer, which currently had no accurate, pre-surgical method of diagnosis nor ability to differentiate between cancerous and benign disease.

Cleo said it had licenced the technology from the Melbourne-based Hudson Institute of Medical Technology and that the tests measured the CXCL10 biomarker.

The company said the tests had been developed for more than 10 years with two studies in more than 500 patients, and had received \$5,000,000 in funding from the National Health and Medical Research Council and Ovarian Cancer Research Foundation.

Cleo said it would develop a pre-surgical Triage Test to determine the chances of a malignant ovarian mass in patients not referred to an oncologist, a Screening Test for early-stage ovarian cancer in patients without symptoms and a Recurrence Test.

The company said funds raised would go to US Food and Drug Administration compliance for the Triage Test, research and development for the Screening and Recurrence tests, general working capital requirements, and payment of corporate and administrative costs.

Cleo said it was unlikely to generate revenue until the Triage Test was commercialized, but believed its available cash and the public offer proceeds should be “adequate to fund its activities and objectives for the two-year period following admission”.

The company said its chief executive officer was former Genetic Technologies chief scientific officer Dr Richard Allman, the chief scientific officer was Dr Andrew Stephens and that Rhythm Biosciences founder Adrien Wing was its chair.

Cleo said Dr Stephens helped develop the tests with the Hudson Institute and was scientific advisor for Invion and AMT Bio.

The company said the offer opened on July 8 and would close on August 4, 2023.

The company said that Taylor Collison was the lead manager of the offer and the prospectus was available at: <https://cleodx.com/prospectus>.

UNIVERSITY OF QUEENSLAND

The University of Queensland says its Centre for Advanced Imaging has opened a \$3 million facility to study and develop the use of radio-metals for cancer therapy.

The University of Queensland said the Australian Cancer Research Foundation (ACRF) had granted \$1.2 million for the facility, which would be named the ACRF Facility for Targeted Radio-metals in Cancer (Afric).

The University said that, alongside its own investment, the National Imaging Facility at the University had invested \$1.2 million in the facility and the Ian Potter Foundation contributed \$180,000.

Centre for Advanced Imaging deputy director Prof Kris Thurecht said the facility was a “welcome addition to the Centre’s extensive research capabilities and would fast-track the development of new cancer therapies for commercial and academic partners”.

The University of Queensland said the new “alpha therapies” had the potential to kill cancer without damaging healthy tissue.

Prof Thurecht said that radio-pharmaceuticals for diagnosis and therapy had been “identified by all levels of government as a... research priority, and Afric firmly positions us as one of the country’s leading capabilities in this space”.

“We will be one of the few places in the country that can produce these specialized isotopes and, in collaboration with our industry partners, we will evaluate and hopefully develop clinical grade product for clinical trials,” Prof Thurecht said.

The University said the grant was supported by industry partners including Telix Pharmaceuticals.

Telix chief scientist Dr Michael Wheatcroft said the facility would “enhance the collaborative development of novel radiopharmaceuticals between companies like Telix, University of Queensland and other research partners by enabling the translational science needed to bring this exciting new technology to patients through future clinical studies”.

BIOXYNE

Bioxyne says Breathe Life Sciences has begun selling its ‘Dr Watson’ over-the-counter, mushroom products through Amazon in the US and Japan.

Bioxyne said the mushroom-based products were “formulated with vitamins and minerals to enhance cognitive function, focus, memory as well as supporting energy levels and are a popular replacement for coffee”.

The company said it was manufacturing marijuana cannabidiol (CBD)-based products and supplying cannabidiol isolates and expected to achieve annual revenue of \$2 million in the year to June 30, 2024 from the UK and Japan.

Bioxyne chief executive officer Sam Watson said the company was “pleased with the rapid uptake of Dr Watson products on Amazon after significant work in the past year in obtaining approvals”.

“We expect to go live on Amazon Australia in the coming months,” Mr Watson said.

“The company holds licences to import and export CBD-based products in Australia, and we await Therapeutics Goods Administration good-manufacturing-practice inspection in September, to enable us to scale existing production facilities,” Mr Watson said.

In May, Bioxyne said it had completed the acquisition of 83 percent of Breathe Life Sciences, appointing chief executive officer Sam Watson as its chief executive officer and a director and chief operating officer Jason Hine as a director (BD: May 22, 2023).

Bioxyne was unchanged at two cents.

ADALTA

Platinum Investment Management says it has increased its substantial shareholding in Adalta from 68,667,239 shares (18.73%) to 87,863,591 shares (19.90%).

The Sydney-based Platinum said that on July 13, 2023 it bought 19,196,352 shares for \$479,909 or 2.5 cents a share.

Last week, Adalta said it had placed \$1.87 million of its rights offer shortfall, including to Platinum Investment Management taking the total raised to \$3.15 million at 2.5 cents a share (BD: July 13, 2023).

Adalta was unchanged at 2.5 cents.

ARGENICA THERAPEUTICS

Chair Geoffrey Pocock says he has increased his shareholding in Argenica but been diluted below five percent.

In June, the Perth-based Mr Pocock said he had become substantial in Argenica with 4,377,000 shares or 5.98 percent.

Today, Mr Pocock said that between June 10 and 14, 2022 he bought 59,690 shares for \$24,602 or 41.2 cents a share, but was diluted by a recent placement.

In June, Argenica said it had raised \$4.0 million at 35.0 cents a share for its phase II trial of ARG-007 for acute ischaemic stroke (BD: Jun 2, 2023).

Mr Pocock said that he held 4,436,690 Argenica shares which Biotech Daily calculates to be holds 4.5 percent of the company.

Argenica was up 1.5 cents or 4.35 percent to 36 cents.

ECHO IQ

Echo IQ director Steven Formica says he has become a substantial shareholder in the company, with 25,516,667 shares or 5.17 percent of the company.

The Perth-based Mr Formica said he bought 250,000 shares through Formica Investments on June 27 at five cents a share, and 5,100,000 shares through Stevsand Investments on July 7, 2023 at eight cents a share.

Echo IQ fell half a cent or three percent to 16 cents.

LUMOS DIAGNOSTICS HOLDINGS

Planet Innovation says its 68,021,060 share-holding in Lumos has been diluted from 19.95 percent to 16.11 percent.

The Melbourne-based Planet Innovation said it was diluted due to the conversion of a convertible note in November and a recent placement.

Last year, Lumos said it had an \$8 million, two-year, convertible note with New York's Lind Partners and Melbourne's SBC Global Investment Fund (BD: Nov 21, 2022).

Last week, Lind Global said it had ceased its substantial shareholding in Lumos, selling shares between July 10 and 12, 2023, and Lumos said it had raised \$4.75 million through a placement at 7.0 cents a share and hoped to raise \$4.75 million through a share plan (BD: Jul 10, 14, 2023).

Lumos was up 1.3 cents or 20.3 percent to 7.7 cents with 64.75 million shares traded.

PYC THERAPEUTICS

David Sietsma says he has increased but been diluted in PYC Therapeutics from 283,996,241 shares (8.96%) to 288,275,006 shares (7.72%).

The Melbourne-based Mr Sietsma did not disclose the price he paid for the acquired shares, as required under the Corporations Act 2001.

In May, PYC said it had raised \$30 million through an “over-bid” placement at 5.5 cents a share (BD: May 11, 2023).

PYC fell 0.4 cents or 5.7 percent to 6.6 cents with 1.1 million shares traded.

ONCOSIL MEDICAL

Oncosil says it has appointed Dr Gabriel Liberatore as a non-executive director.

In May, Oncosil said non-executive chair Otto Buttula would retire at its annual general meeting and chief financial officer and company secretary Karl Pechmann had resigned (BD: May 24, 2023).

The company said Dr Liberatore had more than 25 years' experience in business development, research and development and management positions, and was group chief operating officer at Telix Pharmaceuticals and a strategic advisor to Glytherix.

Biotech Daily previously reported Dr Liberatore had worked at CSL for 12 years, three years at Deloitte Australia and three years at the Melbourne-based Swisse Wellness, and held a Doctor of Philosophy from the University of Melbourne and a Master of Business Administration from La Trobe University (BD: Feb 18, 2019).

Oncosil was unchanged at 1.3 cents.

IMAGION BIOSYSTEMS

Imagion says Robert Proulx has transitioned from president and chief executive officer to non-executive chair.

In April, Imagion said it had extended executive chair Bob Proulx's contract for 12-months while searching for a replacement chief executive officer (BD: Apr 28, 2023).

In June, the company said it had appointed San Diego-based Dr Isaac Bright as chief executive officer, effective from June 20, 2023 (BD: Jun 19, 2023).

Today, Imagion said Mr Proulx was assisting Dr Bright through July as he joined the company.

Imagion fell 0.3 cents or 15 percent to 1.7 cents with 59.3 million shares traded.